Ingo Janssen1, Clara C Chen2, David Taieb3, Nicholas J Patronas4, Corina M Millo5, Karen T Adams6, Joan Nambuba6, Peter Herscovitch5, Samira M Sadowski7, Antonio T Fojo8, Inga Buchmann9, Electron Kebebew7, Karel Pacak10. 1. Program in Adult and Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland Section of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Schleswig Holstein, Lübeck, Germany. 2. Nuclear Medicine Division, Radiology & Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. 3. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France. 4. Section of Neuroradiology, Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. 5. Positron Emission Tomography Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. 6. Program in Adult and Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 7. Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland; and. 8. Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 9. Section of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Schleswig Holstein, Lübeck, Germany. 10. Program in Adult and Reproductive Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland karel@mail.nih.gov.
Abstract
UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs. METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators. RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01). CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.
UNLABELLED: Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT. Therefore, the goal of our study was to assess the clinical utility of this functional imaging modality in parasympathetic head and neck paragangliomas (HNPGLs) compared with anatomic imaging with CT/MRI and other functional imaging modalities, including (18)F-fluorohydroyphenylalanine ((18)F-FDOPA) PET/CT, currently the gold standard in the functional imaging of HNPGLs. METHODS: (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patients with HNPGLs. All patients also underwent (18)F-FDOPA PET/CT, (18)F-FDG PET/CT, and CT/MRI, with 18 patients also undergoing (18)F-fluorodopamine ((18)F-FDA) PET/CT. (18)F-FDOPA PET/CT and CT/MRI served as the imaging comparators. RESULTS: Thirty-eight lesions in 20 patients were detected, with (18)F-FDOPA PET/CT identifying 37 of 38 and CT/MRI identifying 23 of 38 lesions (P < 0.01). All 38 and an additional 7 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT. Significantly fewer lesions were identified by (18)F-FDG PET/CT (24/38, P < 0.01) and (18)F-FDA PET/CT (10/34, P < 0.01). CONCLUSION: (68)Ga-DOTATATE PET/CT identified more lesions than other imaging modalities. With the results of the present study, and the increasing availability and use of DOTA analogs in the therapy of neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional imaging modality for HNPGLs in the near future.
Authors: Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak Journal: Clin Cancer Res Date: 2015-04-14 Impact factor: 12.531
Authors: Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Alexander Kroiss; Daniel Putzer; Andreas Frech; Clemens Decristoforo; Christian Uprimny; Rudolf Wolfgang Gasser; Barry Lynn Shulkin; Christoph Url; Gerlig Widmann; Rupert Prommegger; Georg Mathias Sprinzl; Gustav Fraedrich; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2013-09-27 Impact factor: 9.236
Authors: B E Baysal; J E Willett-Brozick; E C Lawrence; C M Drovdlic; S A Savul; D R McLeod; H A Yee; D E Brackmann; W H Slattery; E N Myers; R E Ferrell; W S Rubinstein Journal: J Med Genet Date: 2002-03 Impact factor: 6.318
Authors: Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak Journal: J Nucl Med Date: 2008-09-15 Impact factor: 10.057
Authors: Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Klaas Pieter Koopmans; Pieter L Jager; Ido P Kema; Michiel N Kerstens; Frans Albers; Robin P F Dullaart Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer Journal: Curr Urol Rep Date: 2021-01-06 Impact factor: 3.092
Authors: Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb Journal: Endocr Relat Cancer Date: 2016-07-12 Impact factor: 5.678
Authors: Abhishek Jha; Alexander Ling; Corina Millo; Garima Gupta; Bruna Viana; Frank I Lin; Peter Herscovitch; Karen T Adams; David Taïeb; Adam R Metwalli; W Marston Linehan; Alessandra Brofferio; Constantine A Stratakis; Electron Kebebew; Maya Lodish; Ali Cahid Civelek; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2017-12-04 Impact factor: 9.236
Authors: Vincent Amodru; Pauline Romanet; Ugo Scemama; Marion Montava; Nicolas Fakhry; Frédéric Sebag; Frédéric Castinetti; Jean-Pierre Lavieille; Anderson Loundou; Arthur Varoquaux; Anne Barlier; Karel Pacak; David Taïeb Journal: Head Neck Date: 2018-12-24 Impact factor: 3.147